TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01079559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplex™ P with Tobramycin
Description: All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simplex™ P
Description: All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
Study: NCT05267392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care RT/RCT
Description: standard of care RT/RCT
Study: NCT05692622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body exercise and respiratory exercise
Description: The study involves an 8-week intervention involving whole-body and respiratory exercises. The whole-body exercise component will involve doing exercises while watching a total of 32 Comic Kids yoga movies. These movies have been adapted to suit the needs and abilities of the target population. For the first 7 weeks of intervention, children will be provided with 4 yoga movies for each week, providing around 67 minutes of exercise in each week. In the last week of intervention, children will have the choice to practice any 4 exercises of their choice from the 28 movies. The respiratory exercise component will involve watching a 10-minute-long movie that involves practicing different styles of breathing and breath holding. Participants will be provided a respiratory trainer to use while practicing these breathing exercises. Children will be asked to practice these breathing exercises by watching the movie at least 2 days each week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body exercise and respiratory exercise
Description: The study involves an 8-week intervention involving whole-body and respiratory exercises. The whole-body exercise component will involve doing exercises while watching a total of 32 Comic Kids yoga movies. These movies have been adapted to suit the needs and abilities of the target population. For the first 7 weeks of intervention, children will be provided with 4 yoga movies for each week, providing around 67 minutes of exercise in each week. In the last week of intervention, children will have the choice to practice any 4 exercises of their choice from the 28 movies. The respiratory exercise component will involve watching a 10-minute-long movie that involves practicing different styles of breathing and breath holding. Participants will be provided a respiratory trainer to use while practicing these breathing exercises. Children will be asked to practice these breathing exercises by watching the movie at least 2 days each week.
Study: NCT06304350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab and platinum containing dual drugs
Description: After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery
Study: NCT06524011

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone
Description: Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone
Description: Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone
Description: Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
Study: NCT05842902

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mPRISM
Description: PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mPRISM
Description: PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.
Study: NCT06684158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: LV：200 mg/m2 iv gtt d1，every 2 weeks (Q2W)
Study: NCT06682221

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Whey protein supplementation.
Description: Protein supplementation will be provided through isolated whey protein, commonly known as whey protein isolate, which was generously donated by the Heroes Science Institute (HSI), as stated in the attached declaration. This whey protein isolate, with a vanilla flavor, is packaged in 25-gram sachets, each providing a total of 20 grams of protein per dose/sachet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation.
Description: Protein supplementation will be provided through isolated whey protein, commonly known as whey protein isolate, which was generously donated by the Heroes Science Institute (HSI), as stated in the attached declaration. This whey protein isolate, with a vanilla flavor, is packaged in 25-gram sachets, each providing a total of 20 grams of protein per dose/sachet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The resistance training protocol in the study included seven exercises: high pull, leg extension, leg curl, bicep curl, triceps pushdown, lateral raise, and machine bench press, taking about 60 minutes per session. The first week focused on familiarizing participants with the exercises to ensure proper execution before intensive training began. Training occurred three times a week for 12 weeks, with each exercise performed in 3 sets of 8 to 12 repetitions and rest periods of 1 to 2 minutes. The load was progressively increased by 2% to 10% weekly, based on participants\&#39; ability to complete repetitions with full range of motion. Assessments were conducted before training and 24 hours after the final session to evaluate the effects on physical and functional parameters.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resistance training
Description: The resistance training protocol in the study included seven exercises: high pull, leg extension, leg curl, bicep curl, triceps pushdown, lateral raise, and machine bench press, taking about 60 minutes per session. The first week focused on familiarizing participants with the exercises to ensure proper execution before intensive training began. Training occurred three times a week for 12 weeks, with each exercise performed in 3 sets of 8 to 12 repetitions and rest periods of 1 to 2 minutes. The load was progressively increased by 2% to 10% weekly, based on participants\&#39; ability to complete repetitions with full range of motion. Assessments were conducted before training and 24 hours after the final session to evaluate the effects on physical and functional parameters.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group Control
Description: The control group will not participate in any of the interventions proposed in the study, meaning it will not receive supplementation or undergo resistance training, serving as a reference to compare the results of the other intervention groups.
Study: NCT06685731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: Laughter Yoga Intervention:~Laughter Yoga is composed of four stages: deep breathing exercises, clapping and warm-up exercises, childlike play, and laughter exercises. These stages are designed to remove barriers to laughter, enhance emotional expression through childlike play, and prepare the lungs for laughter exercises.~Before the Laughter Yoga session begins, participants will be introduced to both the practice itself and to Laughter Yoga in general. The session will then proceed according to the following structure:~Deep Breathing Exercises: Participants inhale through the nose for 4-5 seconds, hold their breath for 2-3 seconds, and exhale through the mouth, with lips pursed, for one second longer than the inhalation, while smiling or laughing. This exercise is performed for 10-15 minutes.~Clapping and Warm-Up Exercises: Participants clap with palms and fingertips touching, keeping their hands parallel. This stimulates acupressure points in the hands. To increase group energy, a
Study: NCT04653402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocelectomy surgery
Description: The standardized hydrocelectomy operation i.e. Eversion of the TVT sac

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocelectomy surgery
Description: The standardized hydrocelectomy operation i.e. Eversion of the TVT sac
Study: NCT06685263

Intervention type: BEHAVIORAL
Intervention: Group 1
Description: The development group comprises 385 individuals. Following the data collection phase of the development group, the independent risk factors for the onset of delirium will be identified through statistical analysis. A delirium prediction model will then be constructed using the identified risk factors.
Study: NCT05469282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood circulation device
Description: Blood circulation device of CGM MB-1701 (Ceragem Master V6)
Study: NCT06685263

Intervention type: BEHAVIORAL
Intervention: Group 2
Description: The validation group comprises 385 individuals. The delirium prediction model created using the data from the development group will be validated by testing the data from the validation group. This will enable the evaluation of the model's fit and calibration in predicting delirium.
Study: NCT06683456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMOTE
Description: The intervention combines psychoeducation, mindfulness skills, emotion regulation skills, and distress tolerance skills, along with self-monitoring of meals, behaviours and feelings.
Study: NCT06101121

Intervention type: DEVICE
Intervention: Lubri-Cream
Description: Lubri-cream is indicated as a surface lubricant for bladder catheterization and cystoscopy. It will be slowly applied on the device, exerting gentle and constant pressure on the tube. Its contents will be evenly distrubuted from the tip to a suitable distance according to the technique to be performed. An individualized dose will be applied according to the technique to be performed and at the discretion of the healthcare professional

Intervention type: DEVICE
Intervention: Lubri-Cream
Description: Lubri-cream is indicated as a surface lubricant for bladder catheterization and cystoscopy. It will be slowly applied on the device, exerting gentle and constant pressure on the tube. Its contents will be evenly distrubuted from the tip to a suitable distance according to the technique to be performed. An individualized dose will be applied according to the technique to be performed and at the discretion of the healthcare professional
Study: NCT06112535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versius Surgical System
Description: Transoral robotic surgery (TORS) using Versius Surgical System. Versius is a robot designed to help surgeons perform surgery. It consists of a set of robotic arms: one of the arms has a camera and a light source on it while the other arms each have a small surgical instrument attached at the end. The surgeon controls each of the arms with hand controllers (joysticks) and can perform surgery with them, while seeing the surgical area on a screen in front of him/her.~The camera and instruments are inserted into the mouth and throat in order to cut out a cancerous tumour.
Study: NCT05657093

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
Study: NCT06684054

Intervention type: DRUG
Intervention: docetaxel, anthracycline, cyclophosphamide
Description: 1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.~2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.~3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.
Study: NCT06682845

Intervention type: OTHER
Intervention: Collection of data in patients' medical files
Description: * Demographic data~* Health data: body mass index, weight, tobacco consumption, history of hyperglycemia/ diabetes mellitus, Eastern Cooperative Oncology Group (ECOG) status, glomerular filtration rate, hemoglobin rate~* Cancer-related data: date of diagnosis, tumoral site, tumor histology type, histology grade, date of first metastases involvement, presence of visceral metastases, presence of liver metastases, presence of lymph node-only metastases~* Treatment-related data: previous line of treatment, co-treatment with anti-PD1, enfortumab vedotin (EV) treatment start date, EV treatment end date, EV posology, presence of EV reduction of dose or increased interval between perfusions, number of EV cycles~* Adverse events (AE)-related data: occurrence of cutaneous AE, grade of cutaneous AE, date of cutaneous AE, type of cutaneous AE, management of cutaneous AE, discontinuation of EV treatment, rechallenge of EV treatment~* Outcomes data: best overall response rate
Study: NCT06682351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1A
Description: 16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1A
Description: 16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1A
Description: 16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MED
Description: 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MED
Description: 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MED
Description: 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.
Study: NCT06303570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514 injection
Description: The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of \>0mm and \<10mm - total injection volume per lipoma: 1 mL ; total of 5 mg CBL-514.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL ; total of 15 mg CBL-514.~Lipoma diameter of \>20mm and ≤30mm - total injection volume per lipoma: 6 mL ; total of 30 mg CBL-514.~Lipoma diameter of \>30mm and ≤40mm - total injection volume per lipoma: 10 mL ; total of 50 mg CBL-514.~Lipoma diameter of \>40mm and ≤50mm - total injection volume per lipoma: 20 mL ; total of 100 mg CBL-514.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of \>0mm and \<10mm - total injection volume per lipoma: 1 mL.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL.~Lipoma diameter of \>20mm and ≤30mm - total injection volume per lipoma: 6 mL.~Lipoma diameter of \>30mm and ≤40mm - total injection volume per lipoma: 10 mL.~Lipoma diameter of \>40mm and ≤50mm - total injection volume per lipoma: 20 mL.
Study: NCT06683872

Intervention type: PROCEDURE
Intervention: surgical myectomy
Description: Our procedure was performed via a right infra-axillary incision (4-5 cm), enter the thoracic cavity through the third intercostal space lateral to the pectoralis major muscle. Generally, neither rib resection nor division of the pectoralis major muscle were required. The intervention utilized femoral-femoral cardiopulmonary bypass (CPB). The aorta was clamped using a Glauber clamp (CardioVision MICAortic Clamp, Cardiomedical GmbH). Myocardial protection was achieved with antegrade Del Nido cardioplegia. After inducing of cardiac asystole, a transverse incision was made in the aorta and the aorta incision was suspended to enhance visualization. A mesh retractor (FEHLING INSTRUMENTS, Karlstein, Germany) was placed in the aortic sinus to protect the aortic leaflets. The extent of the septal myectomy, determined based on preoperative TEE, started 5 mm below the midpoint of the right coronary cusp. It extended counterclockwise towards the anterior commissure of the mitral valve a
Study: NCT06684691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The escape room game will be applied to the students in the intervention group after the theoretical training.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The escape room game will not be applied to the students in the control group after the theoretical training.
Study: NCT06685042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T cell
Description: The investigational medicinal product (IMP) CD19-CAR_Lenti consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis product and processed by using the CliniMACS Prodigy® device (Miltenyi Biotec). CD19-CAR_Lenti is a suspension of fresh CD4/CD8-enriched CD3+ T cells that have been genemodified with a self-inactivating (SIN) lentiviral vector expressing a CAR directed against human CD19. The SIN lentiviral vector is derived from clinically validated viral vectors described in the literature with a fully characterized sequence.
Study: NCT06684132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The H-IMT will be performed in seven sets of three-minute cycles consisting of two minutes of training followed by one minute of rest in the training workload. Each session will consist of 14 minutes of loading and seven minutes of rest for a total of 21 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Stretching exercises for pectoral muscles, neck muscles and back muscles, strengthening exercises for upper extremity and back muscles and posture exercises will be applied.